Single User License
INR 136040
Site License
INR 272080
Corporate User License
INR 408120

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Hypercholesterolemia-Pipeline Review, H2 2016

Hypercholesterolemia-Pipeline Review, H2 2016


  Request for Sample Report

Executive Summary

Hypercholesterolemia-Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hypercholesterolemia-Pipeline Review, H2 2016, provides an overview of the Hypercholesterolemia (Metabolic Disorders) pipeline landscape.

Hypercholesterolemia arises due to high levels of cholesterol in the blood. These abnormal levels may lead to various diseases especially cardiovascular diseases. Cholesterol deposit in the arteries and may cause the narrowing of blood vessels hence restricting the blood flow. The predisposing factors for hypercholesterolemia include various diseases such as diabetes mellitus, renal diseases, obesity etc. The other factors involved are heredity, certain drugs, sedentary lifestyle, smoking, alcoholism, stress and high fat diet. The symptoms for hypercholesterolemia include blocked arteries, leg pain, chest pain and cholesterol deposits. The disease can be controlled by lifestyle changes, dietary changes, and medications.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hypercholesterolemia-Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Hypercholesterolemia (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hypercholesterolemia (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hypercholesterolemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 11, 13, 5, 1, 17, 8 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 7 and 2 molecules, respectively.Hypercholesterolemia.

Hypercholesterolemia (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Hypercholesterolemia (Metabolic Disorders).

The pipeline guide reviews pipeline therapeutics for Hypercholesterolemia (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Hypercholesterolemia (Metabolic Disorders) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Hypercholesterolemia (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Hypercholesterolemia (Metabolic Disorders)

Reasons To Buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Hypercholesterolemia (Metabolic Disorders).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Hypercholesterolemia (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Hypercholesterolemia Overview 9

Therapeutics Development 10

Pipeline Products for Hypercholesterolemia-Overview 10

Pipeline Products for Hypercholesterolemia-Comparative Analysis 11

Hypercholesterolemia-Therapeutics under Development by Companies 12

Hypercholesterolemia-Therapeutics under Investigation by Universities/Institutes 15

Hypercholesterolemia-Pipeline Products Glance 16

Late Stage Products 16

Clinical Stage Products 17

Early Stage Products 18

Unknown Stage Products 19

Hypercholesterolemia-Products under Development by Companies 20

Hypercholesterolemia-Products under Investigation by Universities/Institutes 24

Hypercholesterolemia-Companies Involved in Therapeutics Development 25

3SBio Inc 25

AFFiRiS AG 26

Akcea Therapeutics Inc 27

Alvogen Korea Co Ltd 28

ARMO Biosciences Inc 29

AstraZeneca Plc 30

BioLingus AG 31

Catabasis Pharmaceuticals Inc 32

Chong Kun Dang Pharmaceutical Corp 33

CymaBay Therapeutics Inc 34

Daewon Pharm Co Ltd 35

Dicerna Pharmaceuticals Inc 36

Dybly AG 37

Esperion Therapeutics Inc 38

Gemphire Therapeutics Inc 39

Golden Biotechnology Corp 40

Hanmi Pharmaceuticals Co Ltd 41

Immune Response BioPharma Inc 42

Johnson & Johnson 43

Kadmon Corp LLC 44

Kyorin Pharmaceutical Co Ltd 45

Leading BioSciences Inc 46

LipimetiX Development Inc 47

Lotus Pharmaceutical Co Ltd 48

Merck & Co Inc 49

Pfizer Inc 50

Planet Biotechnology Inc 51

Progenra Inc 52

Regeneron Pharmaceuticals Inc 53

RegenxBio Inc 54

Serometrix LLC 55

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd 56

Solvotrin Therapeutics Ltd 57

The Medicines Company 58

Thetis Pharmaceuticals LLC 59

Viking Therapeutics Inc 60

Zhejiang Hisun Pharmaceutical Co Ltd 61

Hypercholesterolemia-Therapeutics Assessment 62

Assessment by Monotherapy Products 62

Assessment by Combination Products 63

Assessment by Target 64

Assessment by Mechanism of Action 67

Assessment by Route of Administration 70

Assessment by Molecule Type 72

Drug Profiles 74

(aspirin + lisinopril + lovastatin)-Drug Profile 74

(atorvastatin calcium + ezetimibe)-Drug Profile 75

(atorvastatin calcium + ezetimibe)-Drug Profile 76

(atorvastatin calcium + TP-452)-Drug Profile 77

(bempedoic acid + ezetimibe)-Drug Profile 78

(candesartan cilexetil + rosuvastatin calcium)-Drug Profile 79

(ezetimibe + rosuvastatin calcium)-Drug Profile 80

AEM-28-Drug Profile 81

AEM-2802-Drug Profile 83

AEM-2814-Drug Profile 84

alirocumab-Drug Profile 85

AM-0010-Drug Profile 96

anacetrapib-Drug Profile 99

Antibodies for Metabolic Disorders-Drug Profile 101

Antisense Oligonucleotide to Inhibit PCSK9 for Hypercholesterolemia-Drug Profile 102

Antisense Oligonucleotides to Inhibit ApoB100 for Familial Hypercholesterolemia-Drug Profile 103

antroquinonol-Drug Profile 104

ATH-04-Drug Profile 106

ATH-06-Drug Profile 107

bempedoic acid-Drug Profile 108

BSN-272-Drug Profile 118

CAT-2000 Series-Drug Profile 119

CAT-2003-Drug Profile 120

colestilan chloride-Drug Profile 123

D-4F-Drug Profile 124

DCRPCSK-9-Drug Profile 125

Drugs for Hypercholesterolemia-Drug Profile 126

Drugs to Inhibit Sortilin for Hypercholesterolemia-Drug Profile 127

DW-0929-Drug Profile 128

DW-3102-Drug Profile 129

DYB-186-Drug Profile 130

EP-80317-Drug Profile 131

evinacumab-Drug Profile 132

gemcabene calcium-Drug Profile 134

Gene Therapy to Inhibit PCSK9 for Hypercholesterolemia-Drug Profile 136

HCP-1305-Drug Profile 137

HGP-0816-Drug Profile 138

HS-25-Drug Profile 139

inclisiran-Drug Profile 140

IONIS-ANGPTL3LRx-Drug Profile 144

IR-1002-Drug Profile 145

KD-026-Drug Profile 146

MBX-8025-Drug Profile 147

MGL-3196-Drug Profile 150

MGL-3745-Drug Profile 152

MN-002-Drug Profile 153

Monoclonal Antibodies to Inhibit PCSK9 for Hypercholesterolemia-Drug Profile 154

Monoclonal Antibody to Inhibit PCSK9 for Hypercholesterolemia-Drug Profile 155

PF-06446846-Drug Profile 156

Recombinant Protein to Inhibit PCSK9 for Hypercholesterolemia-Drug Profile 157

RGX-501-Drug Profile 158

rosuvastatin calcium-Drug Profile 160

Small Molecule for Hypercholesterolemia-Drug Profile 161

Small Molecule to Inhibit Endothelial Lipase for Hypercholesterolemia-Drug Profile 162

Small Molecule to Inhibit PCSK9 for Hypercholesterolemia-Drug Profile 163

Small Molecule to Inhibit PCSK9 for Hypercholesterolemia-Drug Profile 164

Small Molecules to Inhibit IDOL for Hypercholesterolemia-Drug Profile 165

Small Molecules to Inhibit PCSK9 for Hypercholesterolemia-Drug Profile 166

Small Molecules to Target O2 Radical and HMGCR for Ophthalmology, Cardiovascular, CNS and Metabolic Disorders-Drug Profile 167

ST-0702-Drug Profile 169

SX-PCK9-Drug Profile 170

Synthetic Peptide to Inhibit PCSK9 for Hypercholesterolemia-Drug Profile 171

Vaccine to Target PCSK9 for Hypercholesterolemia-Drug Profile 172

VK-2809-Drug Profile 173

volanesorsen sodium-Drug Profile 176

Hypercholesterolemia-Dormant Projects 182

Hypercholesterolemia-Discontinued Products 189

Hypercholesterolemia-Product Development Milestones 191

Featured News & Press Releases 191

Appendix 208

Methodology 208

Coverage 208

Secondary Research 208

Primary Research 208

Expert Panel Validation 208

Contact Us 208

Disclaimer 209

List of Figures

Number of Products under Development for Hypercholesterolemia, H2 2016 15

Number of Products under Development for Hypercholesterolemia-Comparative Analysis, H2 2016 16

Number of Products under Development by Companies, H2 2016 17

Number of Products under Investigation by Universities/Institutes, H2 2016 20

Comparative Analysis by Clinical Stage Development, H2 2016 22

Comparative Analysis by Early Stage Products, H2 2016 23

Assessment by Monotherapy Products, H2 2016 67

Assessment by Combination Products, H2 2016 68

Number of Products by Top 10 Targets, H2 2016 69

Number of Products by Stage and Top 10 Targets, H2 2016 69

Number of Products by Top 10 Mechanism of Actions, H2 2016 72

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 72

Number of Products by Routes of Administration, H2 2016 75

Number of Products by Stage and Routes of Administration, H2 2016 75

Number of Products by Top 10 Molecule Types, H2 2016 77

Number of Products by Stage and Top 10 Molecule Types, H2 2016 77

List of Tables

Number of Products under Development for Hypercholesterolemia, H2 2016 15

Number of Products under Development for Hypercholesterolemia-Comparative Analysis, H2 2016 16

Number of Products under Development by Companies, H2 2016 17

Number of Products under Development by Companies, H2 2016 (Contd..1) 18

Number of Products under Development by Companies, H2 2016 (Contd..2) 19

Number of Products under Investigation by Universities/Institutes, H2 2016 20

Comparative Analysis by Late Stage Development, H2 2016 21

Comparative Analysis by Clinical Stage Development, H2 2016 22

Comparative Analysis by Early Stage Development, H2 2016 23

Comparative Analysis by Unknown Stage Development, H2 2016 24

Products under Development by Companies, H2 2016 25

Products under Development by Companies, H2 2016 (Contd..1) 26

Products under Development by Companies, H2 2016 (Contd..2) 27

Products under Development by Companies, H2 2016 (Contd..3) 28

Products under Investigation by Universities/Institutes, H2 2016 29

Hypercholesterolemia-Pipeline by 3SBio Inc, H2 2016 30

Hypercholesterolemia-Pipeline by AFFiRiS AG, H2 2016 31

Hypercholesterolemia-Pipeline by Akcea Therapeutics Inc, H2 2016 32

Hypercholesterolemia-Pipeline by Alvogen Korea Co Ltd, H2 2016 33

Hypercholesterolemia-Pipeline by ARMO Biosciences Inc, H2 2016 34

Hypercholesterolemia-Pipeline by AstraZeneca Plc, H2 2016 35

Hypercholesterolemia-Pipeline by BioLingus AG, H2 2016 36

Hypercholesterolemia-Pipeline by Catabasis Pharmaceuticals Inc, H2 2016 37

Hypercholesterolemia-Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2016 38

Hypercholesterolemia-Pipeline by CymaBay Therapeutics Inc, H2 2016 39

Hypercholesterolemia-Pipeline by Daewon Pharm Co Ltd, H2 2016 40

Hypercholesterolemia-Pipeline by Dicerna Pharmaceuticals Inc, H2 2016 41

Hypercholesterolemia-Pipeline by Dybly AG, H2 2016 42

Hypercholesterolemia-Pipeline by Esperion Therapeutics Inc, H2 2016 43

Hypercholesterolemia-Pipeline by Gemphire Therapeutics Inc, H2 2016 44

Hypercholesterolemia-Pipeline by Golden Biotechnology Corp, H2 2016 45

Hypercholesterolemia-Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2016 46

Hypercholesterolemia-Pipeline by Immune Response BioPharma Inc, H2 2016 47

Hypercholesterolemia-Pipeline by Johnson & Johnson, H2 2016 48

Hypercholesterolemia-Pipeline by Kadmon Corp LLC, H2 2016 49

Hypercholesterolemia-Pipeline by Kyorin Pharmaceutical Co Ltd, H2 2016 50

Hypercholesterolemia-Pipeline by Leading BioSciences Inc, H2 2016 51

Hypercholesterolemia-Pipeline by LipimetiX Development Inc, H2 2016 52

Hypercholesterolemia-Pipeline by Lotus Pharmaceutical Co Ltd, H2 2016 53

Hypercholesterolemia-Pipeline by Merck & Co Inc, H2 2016 54

Hypercholesterolemia-Pipeline by Pfizer Inc, H2 2016 55

Hypercholesterolemia-Pipeline by Planet Biotechnology Inc, H2 2016 56

Hypercholesterolemia-Pipeline by Progenra Inc, H2 2016 57

Hypercholesterolemia-Pipeline by Regeneron Pharmaceuticals Inc, H2 2016 58

Hypercholesterolemia-Pipeline by RegenxBio Inc, H2 2016 59

Hypercholesterolemia-Pipeline by Serometrix LLC, H2 2016 60

Hypercholesterolemia-Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd, H2 2016 61

Hypercholesterolemia-Pipeline by Solvotrin Therapeutics Ltd, H2 2016 62

Hypercholesterolemia-Pipeline by The Medicines Company, H2 2016 63

Hypercholesterolemia-Pipeline by Thetis Pharmaceuticals LLC, H2 2016 64

Hypercholesterolemia-Pipeline by Viking Therapeutics Inc, H2 2016 65

Hypercholesterolemia-Pipeline by Zhejiang Hisun Pharmaceutical Co Ltd, H2 2016 66

Assessment by Monotherapy Products, H2 2016 67

Assessment by Combination Products, H2 2016 68

Number of Products by Stage and Target, H2 2016 70

Number of Products by Stage and Mechanism of Action, H2 2016 73

Number of Products by Stage and Route of Administration, H2 2016 76

Number of Products by Stage and Molecule Type, H2 2016 78

Hypercholesterolemia-Dormant Projects, H2 2016 187

Hypercholesterolemia-Dormant Projects (Contd..1), H2 2016 188

Hypercholesterolemia-Dormant Projects (Contd..2), H2 2016 189

Hypercholesterolemia-Dormant Projects (Contd..3), H2 2016 190

Hypercholesterolemia-Dormant Projects (Contd..4), H2 2016 191

Hypercholesterolemia-Dormant Projects (Contd..5), H2 2016 192

Hypercholesterolemia-Dormant Projects (Contd..6), H2 2016 193

Hypercholesterolemia-Discontinued Products, H2 2016 194

Hypercholesterolemia-Discontinued Products (Contd..1), H2 2016 195

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

3SBio Inc , AFFiRiS AG , Akcea Therapeutics Inc , Alvogen Korea Co Ltd , ARMO Biosciences Inc , AstraZeneca Plc , BioLingus AG , Catabasis Pharmaceuticals Inc, Chong Kun Dang Pharmaceutical Corp, CymaBay Therapeutics Inc, Daewon Pharm Co Ltd , Dicerna Pharmaceuticals Inc, Dybly AG , Esperion Therapeutics Inc, Gemphire Therapeutics Inc, Golden Biotechnology Corp, Hanmi Pharmaceuticals Co Ltd, Immune Response BioPharma Inc, Johnson & Johnson , Kadmon Corp LLC , Kyorin Pharmaceutical Co Ltd, Leading BioSciences Inc, LipimetiX Development Inc, Lotus Pharmaceutical Co Ltd, Merck & Co Inc , Pfizer Inc , Planet Biotechnology Inc, Progenra Inc , Regeneron Pharmaceuticals Inc, RegenxBio Inc , Serometrix LLC , Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd, Solvotrin Therapeutics Ltd, The Medicines Company, Thetis Pharmaceuticals LLC, Viking Therapeutics Inc , Zhejiang Hisun Pharmaceutical Co Ltd

Hypercholesterolemia Therapeutic Products under Development, Key Players in Hypercholesterolemia Therapeutics, Hypercholesterolemia Pipeline Overview, Hypercholesterolemia Pipeline, Hypercholesterolemia Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com